» Articles » PMID: 36135376

The Selection of Antibiotic- and Bacteriophage-Resistant Pseudomonas Aeruginosa Is Prevented by Their Combination

Overview
Specialty Microbiology
Date 2022 Sep 22
PMID 36135376
Authors
Affiliations
Soon will be listed here.
Abstract

Bacteria developing resistance compromise the efficacy of antibiotics or bacteriophages (phages). We tested the association of these two antibacterials to circumvent resistance. With the Hollow Fiber Infection Model (HFIM), we mimicked the concentration profile of ciprofloxacin in the lungs of patients treated orally for Pseudomonas aeruginosa infections and, independently, mimicked a single inhaled administration of phages (one or two phages). Each treatment selects for antibiotic- or phage-resistant clones in less than 30 h. In contrast, no bacteria were recovered from the HFIM at 72 h when ciprofloxacin was started 4 h post phage administration, even when increasing the initial bacterial concentration by 1,000-fold. The combination of phages with antibiotics used according to clinical regimens prevents the growth of resistant clones, providing opportunities to downscale the use of multiple antibiotics. In the treatment of bacterial infections, the use of antibiotics or bacteriophages (phages) is limited by the ability of bacteria to develop resistance. The resistance frequency depends on the exposure to antibacterials. Therefore, determination of concentration profiles of antibiotics is key to define optimal regimens during treatments. In the laboratory, the Hollow Fiber Infection Model (HFIM) mimics concentration profiles observed in patients. In this study, we used the HFIM to evaluate the killing efficacy of the combination of phages and ciprofloxacin. We demonstrated that dosing schedule of phages first and the antibiotic second prevent the selection of resistant bacteria. These results demonstrate that combination efficacy relies on a strong initial reduction of the bacterial population by phages followed by antibiotics before any resistant arise.

Citing Articles

Multi-strain phage induced clearance of bacterial infections.

Marchi J, Minh C, Debarbieux L, Weitz J bioRxiv. 2024; .

PMID: 39282405 PMC: 11398464. DOI: 10.1101/2024.09.07.611814.


Bacteriophage-Antibiotic Combination Therapy against .

Santamaria-Corral G, Senhaji-Kacha A, Broncano-Lavado A, Esteban J, Garcia-Quintanilla M Antibiotics (Basel). 2023; 12(7).

PMID: 37508185 PMC: 10376841. DOI: 10.3390/antibiotics12071089.


Bacteriophages: The promising therapeutic approach for enhancing ciprofloxacin efficacy against bacterial infection.

Shariati A, Noei M, Chegini Z J Clin Lab Anal. 2023; 37(9-10):e24932.

PMID: 37377167 PMC: 10388223. DOI: 10.1002/jcla.24932.

References
1.
Wright R, Friman V, Smith M, Brockhurst M . Resistance Evolution against Phage Combinations Depends on the Timing and Order of Exposure. mBio. 2019; 10(5). PMC: 6759759. DOI: 10.1128/mBio.01652-19. View

2.
Engeman E, Freyberger H, Corey B, Ward A, He Y, Nikolich M . Synergistic Killing and Re-Sensitization of to Antibiotics by Phage-Antibiotic Combination Treatment. Pharmaceuticals (Basel). 2021; 14(3). PMC: 7996583. DOI: 10.3390/ph14030184. View

3.
Chow M, Chang R, Li M, Wang Y, Lin Y, Morales S . Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice. Antimicrob Agents Chemother. 2020; 65(1). PMC: 7927809. DOI: 10.1128/AAC.01470-20. View

4.
Diallo K, Dublanchet A . Benefits of Combined Phage-Antibiotic Therapy for the Control of Antibiotic-Resistant Bacteria: A Literature Review. Antibiotics (Basel). 2022; 11(7). PMC: 9311689. DOI: 10.3390/antibiotics11070839. View

5.
Bernheim A, Sorek R . The pan-immune system of bacteria: antiviral defence as a community resource. Nat Rev Microbiol. 2019; 18(2):113-119. DOI: 10.1038/s41579-019-0278-2. View